The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial
Open accessAbstract
Summary Background Valproate is widely accepted as a drug of first choice for patients with generalised onset seizures, and its broad spectrum of efficacy means it is recommended for patients with seizures that are difficult to classify. Lamotrigine and topiramate are also thought to possess broad spectrum activity. The SANAD study aimed to compare the longer-term effects of these drugs in patients with generalised onset seizures or seizures that are difficult to classify. Methods SANAD was an unblinded randomised controlled trial in hospital-based outpatient clinics in the UK. Arm B of the study recruited 716 patients for whom valproate was considered to be standard treatment. Patients were randomly assigned to valproate, lamotrigine, or topiramate between Jan 12, 1999, and Aug 31, 2004, and follow-up data were obtained up to Jan 13, 2006. Primary outcomes were time to treatment failure, and time to 1-year remission, and analysis was by both intention to treat and per protocol. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN38354748. Findings For time to treatment failure, valproate was significantly better than topiramate (hazard ratio 1·57 [95% CI 1·19–2·08]), but there was no significant difference between valproate and lamotrigine (1·25 [0·94–1·68]). For patients with an idiopathic generalised epilepsy, valproate was significantly better than both lamotrigine (1·55 [1·07–2·24] and topiramate (1·89 [1·32–2·70]). For time to 12-month remission valproate was significantly better than lamotrigine overall (0·76 [0·62–0·94]), and for the subgroup with an idiopathic generalised epilepsy 0·68 (0·53–0·89). But there was no significant difference between valproate and topiramate in either the analysis overall or for the subgroup with an idiopathic generalised epilepsy. Interpretation Valproate is better tolerated than topiramate and more efficacious than lamotrigine, and should remain the drug of first choice for many patients with generalised and unclassified epilepsies. However, because of known potential adverse effects of valproate during pregnancy, the benefits for seizure control in women of childbearing years should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60460-7 · Cited by 976
Self-citationMorrow, J. (2006) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.074203 · Cited by 880
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy
Brodie, M. J., UK Lamotrigine/Carbamazepine Monotherapy Trial Group, Richens, A., & Yuen, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90581-2 · Cited by 615
Epilepsy: Frequency Causes and Consequences
Hauser, W. A., & Hesdorffer, D. C. (1990) · Medical Entomology and Zoology · Cited by 587
The longer term outcome of children born to mothers with epilepsy
Adab, N. (2004) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.029132 · Cited by 580
Epilepsy: Frequency, causes and consequences
Messenheimer, J. A. (1991) · Journal of Epilepsy · doi:10.1016/0896-6974(91)90095-z · Cited by 562
Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Motte, J., Trevathan, E., Arvidsson, J. F. V., Barrera, M. N., Mullens, E. L., & Manasco, P. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712183372504 · Cited by 359
Privitera, M. D., Brodie, M. J., Mattson, R. H., Chadwick, D. W., Neto, W., Wang, S., & for the EPMN 105 Study Group (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2003.00093.x · Cited by 249
Self-citationExacerbation of Seizures in Children by Carbamazepine
Snead, O. C., & Hosey, L. C. (1985) · New England Journal of Medicine · doi:10.1056/nejm198510103131503 · Cited by 237
Lamotrigine for Generalized Seizures Associated with the Lennox–Gastaut Syndrome
Trevathan, E., Mullens, E. L., & Manasco, P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809173391218 · Cited by 194
MRC Guidelines for Good Clinical Practice in Clinical Trials
Vere, D. (1999) · Journal of Medical Ethics · doi:10.1136/jme.25.3.280-a · Cited by 159
Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children
Shields, W. D., & Saslow, E. (1983) · Neurology · doi:10.1212/wnl.33.11.1487 · Cited by 145
Nicolson, A., Appleton, R. E., Chadwick, D. W., & Smith, D. (2004) · PubMed Central · Cited by 144
Self-citationDouble-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures
Biton, V., Sackellares, J. C., Vuong, A., Hammer, A. E., Barrett, P. S., & Messenheimer, J. A. (2005) · Neurology · doi:10.1212/01.wnl.0000187118.19221.e4 · Cited by 128
Eriksson, A., Nergårdh, A., & Hoppu, K. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01411.x · Cited by 121
Double‐Blind, Placebo‐Controlled, Lamotrigine in Treatment‐Resistant Generalised Epilepsy
Beran, R. G., Berkovic, S. F., Dunagan, F. M., Vajda, F. J. E., Danta, G., Black, A. B., & Mackenzie, R. (1998) · Epilepsia · doi:10.1111/j.1528-1157.1998.tb01332.x · Cited by 107
Carbamazepine versus Valproate Monotherapy for Epilepsy: A Meta‐analysis
Marson, A. G., Williamson, P. R., Clough, H. E., Hutton, J. L., Chadwick, D. W., & On Behalf Of The Epilepsy Monotherapy Trial Group (2002) · Epilepsia · doi:10.1046/j.1528-1157.2002.20801.x · Cited by 87
Self-citationEthosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents
Posner, E., Mohamed, K., & Marson, A. G. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003032.pub2 · Cited by 74
Self-citationNevitt, S. J., Marson, A. G., Pulman, J., & Smith, C. T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001769.pub2 · Cited by 67
Self-citationSmith, C. T., Marson, A. G., & Williamson, P. R. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001769 · Cited by 41
Self-citation
Cited by
Devinsky, O., Vezzani, A., O'Brien, T. J., Jette, N., Scheffer, I. E., de Curtis, M., & Perucca, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.24 · Cited by 959
Moshé, S. L., Perucca, E., Ryvlin, P., & Tomson, T. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60456-6 · Cited by 905
Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Sabers, A., Perucca, E., & Vajda, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70107-7 · Cited by 751
Glauser, T., Ben‐Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kälviäinen, R., Mattson, R., French, J. A., Perucca, E., Tomson, T., et al. (2013) · Epilepsia · doi:10.1111/epi.12074 · Cited by 721
New avenues for anti-epileptic drug discovery and development
Löscher, W., Klitgaard, H., Twyman, R. E., & Schmidt, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4126 · Cited by 675
Metadata
- Authors
- Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., Cramp, C., Cockerell, O. C., Cooper, P. N., Doughty, J., Eaton, B., Gamble, C., Goulding, P. J., Howell, S. J., Hughes, A., Jackson, M., Jacoby, A., Kellett, M., Lawson, G. R., Leach, J. P., Nicolaides, P., Roberts, R., Shackley, P., Shen, J., Smith, D. F., Smith, P. E., Smith, C. T., Vanoli, A., & Williamson, P. R.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2007-03
- Volume
- 369
- Issue
- 9566
- Pages
- 1016-1026
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2147974822
- Cited by
- 969
- References
- 23
- FWCI
- 34.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.